Medical Aesthetic Device Market Size, Share, Industry, Forecast and outlook (2024-2031)

Report Overview

Medical Aesthetic Device Market is expected to grow at a CAGR of 10.5% during the forecast period (2024-2031).

Medical aesthetic devices are used to treat impairments associated with a person’s aesthetic appearance, such as skin laxity, excessive fat, cellulite, scars, moles, wrinkles, unwanted hair, liver spots, spider veins, and skin discoloration.

Convenient replacement of dysfunctional/missing body parts caused due to accidents, trauma, and other congenital disorders is also possible by use of aesthetic implants. 

Market Summary

For More Insights Request Free Sample

Market Dynamics

The medical aesthetic device market is experiencing significant growth, driven by key dynamics that highlight its evolving landscape. This growth is primarily fueled by the increasing demand for minimally invasive procedures, such as Botox and dermal fillers, which appeal to consumers seeking effective results with minimal downtime. Technological advancements in laser treatments, radiofrequency devices, and ultrasound systems enhance treatment efficacy and patient satisfaction, further propelling market adoption.

Additionally, an aging population is increasingly seeking aesthetic solutions to address signs of aging, while growing awareness fueled by social media influences drives consumer interest in cosmetic procedures. Regulatory approvals for innovative devices are facilitating market expansion, particularly in North America and Asia-Pacific, where rising disposable incomes contribute to greater access. However, challenges such as high treatment costs and stringent regulatory requirements may limit access for certain demographics, especially in emerging markets. Overall, the medical aesthetic device market is poised for continued growth as it adapts to evolving consumer preferences and technological advancements.

COVID-19 Impact on Medical Aesthetic Device Market 

The medical aesthetic devices manufacturers had to shut down the production and supply units due to the lockdown, that was imposed in the beginning of COVID-19 outbreak, globally. According to a survey by Hamilton Fraser Cosmetic Insurance, conducted in March 2020, with 1,360 cosmetic practitioners in the United Kingdom to assess the impact of the pandemic on cosmetic procedures, stated that 99.78% of practitioners revealed that their practice had been affected during the current pandemic. Additionally, consumers are also looking for online cosmetic home treatments. As per the research article published in Journal of Cutaneous and Aesthetic Surgery (September 2020), airborne contaminants are associated with certain lasers, such as ablative fractional lasers and high-peak-power ultrashort-pulsed lasers, such as nano- and picosecond lasers. Also, devices, such as excimer lamp and skin-tightening devices, have probes that come in close contact with the skin, and the risk of transmission of SARS-CoV2 virus is high. Thus, COVID-19 has highly impacted the medical aesthetic devices market worldwide. However, when the situation became normal the market will grow at moderate rate.

Market Segment Analysis

Breast implants segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)        

Breast augmentation, also known as augmentation mammoplasty, is a surgery to increase breast size. It involves placing breast implants under the breast tissue or chest muscles or transferring fat. Breast augmentation procedures have increased over the years. As per a 2019 report by the American Society of Plastic Surgeons (ASPS), the number of breast implant procedures increased considerably in the United States, from 212,500 in 2000 to 299,715 in 2019.

Additionally, the increasing product launches and advancements in technologies boosted the growth of the market. For instance, in 2019, Evonik and BellaSeno GmbH entered a long-term agreement for the use of a RESOMER bioresorbable polymer for an innovative breast implant technology. The RESOMER polymer features mechanical properties and a degradation profile that allow the scaffold to safely absorb at a rate that matches the formation of the patient's tissue and is designed to be implanted after breast reconstruction, augmentation, or revision surgery. Thus, owing to the aforementioned factors, the breast implants segment is expected to grow over the forecast period.

Market Geographical Share

North America region holds the largest market share of global medical aesthetic device market

North America is expected to dominate the overall medical aesthetic device market in the forecast period. According to the American Society of Plastic Surgeons, 18.1 million cosmetic procedures were recorded in 2019, an increase of 2%, from 2018, which included around 1.8 million cosmetic surgical and 16.3 million cosmetic minimally invasive procedures. Also, the high concentration of major players in the region and subsequent product launches play a vital role in the growth of the studied market in the region. For instance, in June 2020, E.S.I. The novel. a part of Essence Group, launched JOLI360, a new skin rejuvenation solution that can measure three skin parameters: hydration, elasticity, and sebum. Thus, the aforementioned factors are expected to drive the market over the forecast period in the region.

Companies and Competitive Landscape

The medical aesthetic device market is moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Abbvie Inc. (Allergan PLC), Alma Lasers Ltd (Sisram Med), Bausch Health Companies Inc. (Solta Medical Inc.), Cutera Inc., El. En. (Asclepion Laser Technologies), Lumenis Inc., Sciton Inc., and Syneron Medical Ltd, DEKA Laser Technologies, Sigmacon Medical among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Medical Aesthetic Device Market globally. For instance, in March 2020, JW Pharmaceutical launched Initium, a hyaluronic acid filler, in the South Korean market.  

Key Developments

• Crescita Therapeutics Launches MicronJet™ 600
  On July 17, 2024, Crescita Therapeutics announced the upcoming launch of its MicronJet™ 600, an advanced intradermal delivery device designed for the Canadian medical aesthetics market. This innovative device utilizes MEMS technology for a highly effective and virtually pain-free delivery of aesthetic products. It is particularly suited for sensitive areas such as around the eyes and neck, enhancing precision in treatments. The launch is anticipated in the first half of 2025 after obtaining regulatory approval from Health Canada.
• Cartessa Aesthetics Introduces New Technologies
  In October 2024, Cartessa Aesthetics unveiled three new devices at the Inner Circle Invitational, including the Prisma, which combines intense pulsed light (IPL) with electro-muscle stimulation and radiofrequency technology. This device aims to redefine photofacials by addressing multiple signs of aging. Additionally, Cartessa introduced SKNLAB, an aqua-dermabrasion system that incorporates energy modalities for customizable facial treatments, enhancing their portfolio in the aesthetic device market.
• Merz Aesthetics Launches Ultherapy PRIME®
  On January 23, 2025, Merz Aesthetics launched its new Ultherapy PRIME® device in the EMEA region. This evolution of their non-invasive skin lifting technology offers customizable treatment options to improve skin health and enhance long-term confidence. The launch was highlighted at the IMCAS World Congress, where Merz emphasized its commitment to innovation in regenerative aesthetics.    

Abbvie Inc. (Allergan Aesthetics)

Overview:

Allergan Aesthetics develops, manufactures, and markets a portfolio of leading brands and products including facial injectable, body contouring, plastics and more. The company is a subsidiary of Abbvie Inc.

Product Portfolio:

Natrelle Breast Implants:  Natrelle Breast Implants are approved for the following.

Breast augmentation for women at least 22 years old for silicone-filled implants and for women at least 18 years old for saline-filled implants. Breast augmentation includes primary breast augmentation to increase the breast size and revision surgery to correct or improve the result of a primary breast augmentation.

Breast reconstruction. This includes primary breast reconstruction to replace breast tissue that has been removed due to cancer or trauma or that has failed to develop properly due to a severe breast abnormality. This also includes revision surgery to correct or improve the result of a primary breast reconstruction.